RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue44,5094,48420,38328,895
Cost of Revenue47,19046,26963,44662,825
Gross Profit-2,681-41,785-43,063-33,930
Operating Expenses
Research Development46,90346,90346,90346,903
Selling General and Administrative70,00237,83120,90817,813
Non Recurring----
Others----
Total Operating Expenses117,19284,10084,35480,638
Operating Income or Loss-72,683-79,616-63,971-51,743
Income from Continuing Operations
Total Other Income/Expenses Net2,2031,624-5,245279
Earnings Before Interest and Taxes-72,683-79,616-63,971-51,743
Interest Expense----
Income Before Tax-70,480-77,992-69,216-51,464
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-70,480-77,992-69,216-51,464
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-70,480-77,992-69,216-51,464
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-70,480-77,992-69,216-51,464